SCHEDULE: Orca Capital AG Discloses 9.9% Stake in Rani Therapeutics Holdings, Inc.
Beneficial Ownership Report
Orca Capital AG has reported a significant 9.9% beneficial ownership stake in Rani Therapeutics Holdings, Inc., holding 4,354,000 shares of Class A Common Stock.
Summary
- Orca Capital AG, a German entity, has filed a Schedule 13G indicating beneficial ownership of 4,354,000 shares of Rani Therapeutics Holdings, Inc.'s Class A Common Stock.
- This ownership represents 9.9% of the Issuer's Class A Common Stock outstanding.
- The calculation is based on an aggregate of 43,606,522 shares of Class A Common Stock outstanding immediately after the completion of Rani Therapeutics' registered offering.
- Orca Capital AG also holds 3,146,000 shares of Class A Common Stock issuable upon the exercise of pre-funded warrants.
- A '9.99% Blocker' provision prevents Orca Capital AG from exercising these pre-funded warrants if it would result in beneficial ownership exceeding 9.99% of the Issuer's outstanding Class A Common Stock.
Sentiment
Score: 7
Explanation: The disclosure of a significant 9.9% stake by an institutional investor like Orca Capital AG is generally positive, indicating confidence in the company. However, the 9.99% blocker on warrant exercise introduces a slight limitation on potential future investment by this specific entity.
Positives
- A significant institutional investor, Orca Capital AG, has taken a substantial 9.9% stake in Rani Therapeutics Holdings, Inc., which can be viewed as a vote of confidence in the company's prospects.
Negatives
- The '9.99% Blocker' limits Orca Capital AG's immediate ability to increase its beneficial ownership beyond the current reported percentage, even with the pre-funded warrants it holds.
Risks
- The '9.99% Blocker' restricts Orca Capital AG from exercising its pre-funded warrants if doing so would cause its beneficial ownership to exceed 9.99% of Rani Therapeutics' Class A Common Stock, potentially limiting future capital deployment or influence by this investor.
Future Outlook
The document does not provide forward-looking statements or guidance regarding the company's future financial performance or strategic direction, focusing solely on beneficial ownership disclosure.
Industry Context
Schedule 13G filings are typically made by passive institutional investors who acquire a significant stake (over 5%) in a company's stock. Such disclosures indicate that a large investor believes in the long-term value of the company without intending to influence or change control, often seen as a positive signal in the market.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Restriction | The pre-funded warrants held by Orca Capital AG include a '9.99% Blocker' provision, preventing the exercise of warrants if it would result in beneficial ownership exceeding 9.99% of the Issuer's outstanding Class A Common Stock. | NA | This provision limits the concentration of ownership by Orca Capital AG and ensures that their stake remains below a certain threshold, potentially impacting their ability to exert greater influence or increase their investment beyond the current reported percentage. |
Stakeholder Impact
- Shareholders may view the significant stake taken by Orca Capital AG as a positive indicator of institutional confidence in Rani Therapeutics Holdings, Inc.'s future.
- The '9.99% Blocker' provision ensures that no single entity, specifically Orca Capital AG, can accumulate more than 9.99% beneficial ownership through the exercise of these specific warrants, which could impact future capital structure and control dynamics.
Key Dates
| Date | Description |
|---|---|
| 07/14/2025 | Date of event which required the filing of this statement. |
| 07/16/2025 | Date the Issuer's Prospectus pursuant to Rule 424(b)(4) was filed with the SEC, describing the terms of the pre-funded warrants. |
| 07/17/2025 | Date the Schedule 13G was signed by Orca Capital AG. |
Keywords
Rani Therapeutics Holdings Inc, Orca Capital AG, Schedule 13G, Beneficial Ownership, Class A Common Stock, Pre-funded Warrants, 9.99% Blocker, Institutional Investment, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.